1 Study Coverage
1.1 RNA-Based Therapeutics and Vaccines Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million) Introduction
1.2 Global RNA-Based Therapeutics and Vaccines Outlook 2017 VS 2022 VS 2028
1.2.1 Global RNA-Based Therapeutics and Vaccines Market Size for the Year 2017-2028
1.2.2 Global RNA-Based Therapeutics and Vaccines Market Size for the Year 2017-2028
1.3 RNA-Based Therapeutics and Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States RNA-Based Therapeutics and Vaccines in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of RNA-Based Therapeutics and Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 RNA-Based Therapeutics and Vaccines Market Dynamics
1.4.1 RNA-Based Therapeutics and Vaccines Industry Trends
1.4.2 RNA-Based Therapeutics and Vaccines Market Drivers
1.4.3 RNA-Based Therapeutics and Vaccines Market Challenges
1.4.4 RNA-Based Therapeutics and Vaccines Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 RNA-Based Therapeutics and Vaccines by Type
2.1 RNA-Based Therapeutics and Vaccines Market Segment by Type
2.1.1 RNA-Based Therapeutics
2.1.2 RNA-Based Vaccines
2.2 Global RNA-Based Therapeutics and Vaccines Market Size by Type (2017, 2022 & 2028)
2.3 Global RNA-Based Therapeutics and Vaccines Market Size by Type (2017-2028)
2.4 United States RNA-Based Therapeutics and Vaccines Market Size by Type (2017, 2022 & 2028)
2.5 United States RNA-Based Therapeutics and Vaccines Market Size by Type (2017-2028)
3 RNA-Based Therapeutics and Vaccines by Application
3.1 RNA-Based Therapeutics and Vaccines Market Segment by Application
3.1.1 Oncology
3.1.2 Immunology
3.1.3 Ophthalmology
3.1.4 Cardiovascular Diseases
3.1.5 Infectious Diseases
3.1.6 Genetic Diseases
3.1.7 Others
3.2 Global RNA-Based Therapeutics and Vaccines Market Size by Application (2017, 2022 & 2028)
3.3 Global RNA-Based Therapeutics and Vaccines Market Size by Application (2017-2028)
3.4 United States RNA-Based Therapeutics and Vaccines Market Size by Application (2017, 2022 & 2028)
3.5 United States RNA-Based Therapeutics and Vaccines Market Size by Application (2017-2028)
4 Global RNA-Based Therapeutics and Vaccines Competitor Landscape by Company
4.1 Global RNA-Based Therapeutics and Vaccines Market Size by Company
4.1.1 Top Global RNA-Based Therapeutics and Vaccines Companies Ranked by Revenue (2021)
4.1.2 Global RNA-Based Therapeutics and Vaccines Revenue by Player (2017-2022)
4.2 Global RNA-Based Therapeutics and Vaccines Concentration Ratio (CR)
4.2.1 RNA-Based Therapeutics and Vaccines Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of RNA-Based Therapeutics and Vaccines in 2021
4.2.3 Global RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global RNA-Based Therapeutics and Vaccines Headquarters, Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million) Type
4.3.1 Global RNA-Based Therapeutics and Vaccines Headquarters and Area Served
4.3.2 Global RNA-Based Therapeutics and Vaccines Companies Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into RNA-Based Therapeutics and Vaccines Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States RNA-Based Therapeutics and Vaccines Market Size by Company
4.5.1 Top RNA-Based Therapeutics and Vaccines Players in United States, Ranked by Revenue (2021)
4.5.2 United States RNA-Based Therapeutics and Vaccines Revenue by Players (2020, 2021 & 2022)
5 Global RNA-Based Therapeutics and Vaccines Market Size by Region
5.1 Global RNA-Based Therapeutics and Vaccines Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global RNA-Based Therapeutics and Vaccines Market Size by Region (2017-2028)
5.2.1 Global RNA-Based Therapeutics and Vaccines Market Size by Region: 2017-2022
5.2.2 Global RNA-Based Therapeutics and Vaccines Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.1.2 North America RNA-Based Therapeutics and Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.3.2 Europe RNA-Based Therapeutics and Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.4.2 Latin America RNA-Based Therapeutics and Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa RNA-Based Therapeutics and Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Alnylam Pharmaceuticals
7.1.1 Alnylam Pharmaceuticals Company Details
7.1.2 Alnylam Pharmaceuticals Business Overview
7.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
7.1.4 Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.1.5 Alnylam Pharmaceuticals Recent Development
7.2 Arbutus Biopharma
7.2.1 Arbutus Biopharma Company Details
7.2.2 Arbutus Biopharma Business Overview
7.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Introduction
7.2.4 Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.2.5 Arbutus Biopharma Recent Development
7.3 Arrowhead Pharmaceuticals
7.3.1 Arrowhead Pharmaceuticals Company Details
7.3.2 Arrowhead Pharmaceuticals Business Overview
7.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
7.3.4 Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.3.5 Arrowhead Pharmaceuticals Recent Development
7.4 BioNTech
7.4.1 BioNTech Company Details
7.4.2 BioNTech Business Overview
7.4.3 BioNTech RNA-Based Therapeutics and Vaccines Introduction
7.4.4 BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.4.5 BioNTech Recent Development
7.5 CureVac
7.5.1 CureVac Company Details
7.5.2 CureVac Business Overview
7.5.3 CureVac RNA-Based Therapeutics and Vaccines Introduction
7.5.4 CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.5.5 CureVac Recent Development
7.6 Dicerna Pharmaceuticals
7.6.1 Dicerna Pharmaceuticals Company Details
7.6.2 Dicerna Pharmaceuticals Business Overview
7.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
7.6.4 Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.6.5 Dicerna Pharmaceuticals Recent Development
7.7 Regulus Therapeutics
7.7.1 Regulus Therapeutics Company Details
7.7.2 Regulus Therapeutics Business Overview
7.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Introduction
7.7.4 Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.7.5 Regulus Therapeutics Recent Development
7.8 Marina Biotech
7.8.1 Marina Biotech Company Details
7.8.2 Marina Biotech Business Overview
7.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Introduction
7.8.4 Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.8.5 Marina Biotech Recent Development
7.9 MiRagen Therapeutics
7.9.1 MiRagen Therapeutics Company Details
7.9.2 MiRagen Therapeutics Business Overview
7.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Introduction
7.9.4 MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.9.5 MiRagen Therapeutics Recent Development
7.10 Moderna Therapeutics
7.10.1 Moderna Therapeutics Company Details
7.10.2 Moderna Therapeutics Business Overview
7.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Introduction
7.10.4 Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.10.5 Moderna Therapeutics Recent Development
7.11 Quark Pharmaceuticals
7.11.1 Quark Pharmaceuticals Company Details
7.11.2 Quark Pharmaceuticals Business Overview
7.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
7.11.4 Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.11.5 Quark Pharmaceuticals Recent Development
7.12 Roche
7.12.1 Roche Company Details
7.12.2 Roche Business Overview
7.12.3 Roche RNA-Based Therapeutics and Vaccines Introduction
7.12.4 Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.12.5 Roche Recent Development
7.13 Sylentis
7.13.1 Sylentis Company Details
7.13.2 Sylentis Business Overview
7.13.3 Sylentis RNA-Based Therapeutics and Vaccines Introduction
7.13.4 Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.13.5 Sylentis Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
